Abstract
Wilms' tumor (WT), or nephroblastoma, is a common childhood renal neoplasm that is exceptionally rare in adults. While radiological imaging is an excellent diagnostic tool, histomorphologic diagnosis in adults can be challenging due to limited sampling and the rarity of the condition, which often leads to its exclusion from differential diagnoses. We report the case of a 21-year-old woman diagnosed with adult Wilms tumor (AWT) after presenting with a palpable left abdominal mass. Following the Children's Oncology Group (COG) protocol, she underwent a total left nephrectomy. Histology revealed a classic triphasic pattern with blastemal (40%), epithelial (45%), and stromal (15%) components. Despite initial adjuvant chemotherapy, the patient developed pulmonary and liver metastases nine months post-surgery. A more intensive chemotherapy regimen resulted in a favorable response, and the patient remained disease-free at her 26-month follow-up. This case underscores the diagnostic and therapeutic complexities of AWT and the efficacy of pediatric protocols in adult patients.
Introduction
Wilms’ tumor accounts for nearly 90% of pediatric renal cancers but represents less than 1% of adult renal malignancies. Because of this extreme rarity, clinicians often default to a diagnosis of Renal Cell Carcinoma (RCC) when presented with an adult renal mass. AWT presents with symptoms identical to RCC—flank pain, hematuria, and a palpable mass—but requires a vastly different therapeutic approach. Currently, there are no universally accepted treatment guidelines for adults, forcing oncologists to adapt pediatric protocols from the Children's Oncology Group (COG) or the International Society of Pediatric Oncology (SIOP).
Case Presentation and Methods
A 21-year-old female presented with a 13 cm heterogeneous mass in the left kidney, identified via abdominal ultrasound and enhanced CT. Following standard COG protocol, the patient underwent a total left nephrectomy.
Diagnostic techniques employed included:
- Histopathology: Analysis of the resected tumor to identify the characteristic "triphasic" pattern.
- Immunohistochemistry (IHC): Markers such as WT1, PAX8, and Vimentin were used to confirm the tumor's renal origin.
- Molecular Analysis: Next-generation sequencing (NGS) was performed to identify genetic drivers, specifically mutations in the TP53 gene.
Pathological and Molecular Insights
The definitive diagnosis of AWT rests on identifying three distinct histological components: blastemal, epithelial, and stromal. In this case, the tumor exhibited a classic triphasic signature.
While the tumor was initially classified as having "favorable histology" (non-anaplastic), molecular profiling revealed a mutation in the TP53 gene (17p13). This genetic marker is often associated with aggressive recurrence and suggests that molecular profiling may provide more accurate prognostic value than morphology alone in adult presentations.
Treatment and Clinical Course
Post-nephrectomy, the patient began adjuvant chemotherapy with Dactinomycin and Doxorubicin. However, nine months later, imaging detected significant tumor burden in the lungs and liver. Due to the extent of the metastases, surgical intervention was not feasible. The clinical team pivoted to a triple-drug pediatric regimen consisting of Vincristine, Dactinomycin, and Doxorubicin.
This intensive salvage therapy proved highly effective. The patient achieved a complete clinical response and remained disease-free for 26 months following the initiation of the second-line treatment.
Discussion and Conclusion
This case highlights the critical need for including AWT in the differential diagnosis of adult renal masses. The successful outcome demonstrates that pediatric chemotherapy protocols can be highly effective in adults, even in the presence of heavy metastatic disease.
Future management of AWT should likely incorporate routine Next-Generation Sequencing (NGS) to identify high-risk markers like TP53, WT1, and IGF2 early in the diagnostic process. Furthermore, the development of age-stratified protocols is necessary to address the more aggressive biology often observed in adult patients. Although this patient was lost to follow-up after 26 months, her initial recovery provides a strong argument for the use of intensive multi-agent chemotherapy in treating recurrent adult nephroblastoma.
Summary updated